Free Trial

VdL Confirms AstraZeneca's Application For EMA Vaccine Approval

EU

European Commission President Ursula von der Leyen tweets: "Good news! @AstraZeneca has applied to @EMA_News to have its vaccine authorised in the EU. @EMA_News will assess the vaccine's safety & efficacy. Once the vaccine receives a positive scientific opinion, we will work full speed to authorise its use in Europe."

  • The EU has so far approved the Pfizer/BioNTech and Moderna vaccines for use in the bloc.
  • As in the UK (where it has already been approved) a rollout of the AstraZeneca/Oxford University vaccine would likely improve the speed of rollout (it does not need to be kept at superchilled temperatures) and lower costs (per dose it is around EUR1.78 compared to EUR12 for the Pfizer jab and EUR18 for Moderna's).
  • The EU has ordered 300mn doses of the AstraZeneca vaccine pending approval.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.